Carrie Brownstein
Equibles does not estimate personal net worth.
Get an email with a short summary when Cellectis S.A. publishes a filing, an earnings call transcript or a press release.
Get CLLS alertsAbout Carrie Brownstein
Earlier roles on record: Board Member at Shattuck Labs, Inc. (STTK) until August 25, 2025. Shattuck Labs, Inc. reported in an 8-K filed August 26, 2025 that Carrie Brownstein resigned as Class I director, effective August 25, 2025. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed January 25, 2024 that Carrie Brownstein resigned as Chief Medical Officer, effective January 19, 2024. The proxy statement of Zentalis Pharmaceuticals, Inc. reports total compensation of $8,830,657 for Carrie Brownstein in fiscal 2022, including a base salary of $127,500. Cellectis S.A. is classified in the Biotechnology industry within the Healthcare sector.
“Effective on the Closing Date, Tyler Brous, a Class I director, Dr. Carrie Brownstein, a Class I director, Michael Lee, a Class I director, and Dr. Kate Sasser, a Class II director, resigned from the Board of Directors (the "Board") of the Company as well as any respective committees of the Board of which they were members.”
“On and effective as of the Transition Date, Dr. Brownstein stepped down for personal reasons.”
Affiliation history
-
Cellectis S.A. (CLLS)
Source not stated
Current -
Zentalis Pharmaceuticals, Inc. (ZNTL)
Proxy statement
Start not stated–2024-01-19
-
Start not stated–2025-08-25
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Chief Medical Officer | $127,500 | $8,830,657 |